Our case eliminates the possibility of imatinib as the sole cause since our patient received a diagnosis of simultaneous plasma cell myeloma, CML, and a Jak2 mutation positive myeloproliferative disorder (MPD) arising de novo, prior to any treatment. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.